Next-Generation Antibodies Market To Be Worth $11.6bn In 2020, A New Visiongain Study Predicts

07 September 2018
Pharma

A new report by visiongain, published in April 2016, forecasts that the worldwide next-generation antibodies market will generate $11.6 billion in 2020. That revenue forecast and others appear in Next-Generation Antibody Therapies Market Forecast 2016-2026: Explore Developments and Sales Potentials for ADCs, Engineered Antibodies, ALPs, Bispecific and Biosimilar Agents.

Visiongain is a business information publisher and consultancy based in London, UK. Its purpose is to help companies and other organisations assess the potentials of industries and market in healthcare and other fields.

Arshad Ahad, a senior pharmaceutical industry analyst in visiongain, said:
“Next-generation antibody therapies are treatments based on antibodies that have been engineered or otherwise designed to have advantages over simple monoclonal antibodies. Next-generation antibodies are establishing themselves in the market, seven years after the current crop of novel therapies first reached the market with the approval of Kalbitor and Removab in 2009.

“Sales of Adcetris and Kadcyla constitute the majority of revenues in the market in 2016, but over the next ten years rapid growth will stem from the launch of biosimilar drugs, and later from new engineered and bispecific antibody therapies. A strong and varied R&D pipeline will propel this market to new heights from 2016 to 2026.”

First visiongain’s new study provides revenue forecasts to 2026 for five submarkets and the overarching world market:

• Antibody-drug conjugates
• Engineered antibodies
• Bispecific antibodies
• Antibody fragments and ALPs
• Biosimilar antibodies.

In addition that investigation shows revenue forecasts to 2026 for seven drugs:

• Adcetris
• Kadcyla
• Gazyva/Gazyvaro
• Poteligeo
• Removab
• Blincyto
• Kalbitor.

That analysis also shows revenue forecasts to 2026 for four regional markets:

• US
• EU5 group
• Asia-Pacific region
• Latin America
• Rest of the world.

The new report discusses forces stimulating sales growth over the next ten years, as well as forces restraining that industry and market. That work also shows interviews with three companies – Ablynx, arGEN-X and Mersana Therapeutics.

Next-Generation Antibody Therapies Market Forecast 2016-2026 adds to visiongain’s reports on industries and markets in healthcare. Together those studies cover pharmaceuticals, biotechnology, outsourced services, diagnostics and medical devices.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever